Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Accepted manuscripts
    • Issue in progress
    • Latest complete issue
    • Issue archive
    • Archive by article type
    • Interviews
    • Sign up for alerts
  • About us
    • About BiO
    • Editors and Board
    • Editor biographies
    • Grants and funding
    • Journal Meetings
    • Workshops
    • The Company of Biologists
    • Journal news
  • For authors
    • Submit a manuscript
    • Aims and scope
    • Presubmission enquiries
    • Article types
    • Manuscript preparation
    • Cover suggestions
    • Editorial process
    • Promoting your paper
    • Open Access
  • Journal info
    • Journal policies
    • Rights and permissions
    • Media policies
    • Reviewer guide
    • Sign up for alerts
  • Contact
    • Contact BiO
    • Advertising
    • Feedback
  • COB
    • About The Company of Biologists
    • Development
    • Journal of Cell Science
    • Journal of Experimental Biology
    • Disease Models & Mechanisms
    • Biology Open

User menu

  • Log in

Search

  • Advanced search
Biology Open
  • COB
    • About The Company of Biologists
    • Development
    • Journal of Cell Science
    • Journal of Experimental Biology
    • Disease Models & Mechanisms
    • Biology Open

supporting biologistsinspiring biology

Biology Open

Advanced search

RSS   Twitter   Facebook   YouTube

  • Home
  • Articles
    • Accepted manuscripts
    • Issue in progress
    • Latest complete issue
    • Issue archive
    • Archive by article type
    • Interviews
    • Sign up for alerts
  • About us
    • About BiO
    • Editors and Board
    • Editor biographies
    • Grants and funding
    • Journal Meetings
    • Workshops
    • The Company of Biologists
    • Journal news
  • For authors
    • Submit a manuscript
    • Aims and scope
    • Presubmission enquiries
    • Article types
    • Manuscript preparation
    • Cover suggestions
    • Editorial process
    • Promoting your paper
    • Open Access
  • Journal info
    • Journal policies
    • Rights and permissions
    • Media policies
    • Reviewer guide
    • Sign up for alerts
  • Contact
    • Contact BiO
    • Advertising
    • Feedback
Research Article
Targeted mutagenesis using CRISPR/Cas system in medaka
Satoshi Ansai, Masato Kinoshita
Biology Open 2014 3: 362-371; doi: 10.1242/bio.20148177
Satoshi Ansai
Division of Applied Biosciences, Graduate School of Agriculture, Kyoto University, Kitashirakawa-Oiwake-cho, Sakyo-ku, Kyoto 606-8502, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Masato Kinoshita
Division of Applied Biosciences, Graduate School of Agriculture, Kyoto University, Kitashirakawa-Oiwake-cho, Sakyo-ku, Kyoto 606-8502, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: kinoshit@kais.kyoto-u.ac.jp
  • Article
  • Figures & tables
  • Supp info
  • Info & metrics
  • eLetters
  • PDF + SI
  • PDF
Loading

Article Figures & Tables

Figures

  • Fig. 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 1. Induction of somatic mutations with CRISPR/Cas-mediated RGENs.

    (A) Schematic representation of the genomic structure of the DJ-1 gene. Coding and untranslated exon regions are shown as solid and open boxes, respectively. The 20-bp target sequence of sgRNA no. 1 is indicated in green box, adjacent to NGG protospacer adjacent motif (PAM) sequence in light blue box. Red and blue boxes indicate the left and right recognition sequence of previously described TALENs (Ansai et al., 2013). (B) The sgRNA sequence for target site no. 1. First 20-nts sequence interacts with the complementary strand of the DNA target site. Red and green letters indicate the sequence required by T7 RNA polymerase and the customizable targeting sequence, respectively. (C) Heteroduplex mobility assay (HMA) in embryos injected with a mixture containing 100 ng/µL of Cas9 RNA and 25 ng/µL of sgRNA no. 1. Multiple heteroduplex bands were shown in PCR amplicons from each the RGEN-injected embryo (#1–6), whereas a single band was shown from each “Control” embryo without injection of the RGENs. (D,E) Subcloned sequences observed in the RGEN-injected embryos #1 (D) and #2 (E). Red dashes and letters indicate the identified mutations. The sgRNA targeting sequence and PAM indicate in green and light blue boxes, respectively. The size of deletions and insertions are shown to the right of each mutated sequence (Δ; deletions, +; insertions). Numbers on the right edge indicate the numbers of mutated clones identified from all analyzed clones from each embryo.

  • Fig. 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 2. Somatic mutations induced at genomic sequences not containing GG at the 5′ ends.

    (A) Schematic illustration of the additional RGEN targeting sequences on the 2nd exon of DJ-1 gene. Target site no. 2 and 3 do not contain GG at their 5′ ends, while target site no. 1 starts with the sequence GG. The targeting sequence of sgRNA is indicated in green box, adjacent to NGG protospacer adjacent motif (PAM) sequence in light blue box. (B,C) The sequences of sgRNAs for target site no. 2 (B) and 3 (C). Red and green letters indicate the sequence required by T7 RNA polymerase and the customizable targeting sequence, respectively. Two sgRNAs were designed for each target site. The sgRNA no. 2a and 3a contain the 18-nts sequence complementary to their genomic target site, while the sgRNA no. 2b and 3b contain the 20-nts sequence. These sgRNAs also contain 1- or 2-nt mismatches to their genomic target sequence at 5′ end. (D) Heteroduplex mobility assay (HMA) in embryos injected with a mixture containing 100 ng/µL of Cas9 RNA and 25 ng/µL of sgRNA. Multiple heteroduplex bands were shown in PCR amplicons from each the RGEN-injected embryo, whereas a single band was shown from each “Control” embryo without the injection of the RGENs. (E–H) Subcloned sequences observed in the embryos injected with sgRNA no. 2a (E), 2b (F), 3a (G), or 3b (H). Red dashes and letters indicate the identified mutations. The sgRNA targeting sequence and PAM indicate in green and light blue boxes, respectively. The size of deletions and insertions are shown to the right of each mutated sequence (Δ; deletions, +; insertions). Numbers on the right edge indicate the numbers of mutated clones identified from all analyzed clones from each embryo.

  • Fig. 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 3. Dose-dependent mutagenesis by the RGENs.

    (A) Schematic illustration of restriction fragment length polymorphism (RFLP) analysis to calculate mutation frequencies. The sgRNA no. 3a contatin an AluI restriction enzyme site (Red letters with underline) on the potential cleavage site indicated by an arrowhead. A 285 bp fragment amplified using primers DJ1-FW2 and DJ1-RV1 produces both 75 bp (a) and 210 bp fragments by AluI digestion in wild type. (B) Gel image of AluI-digested fragments analyzed in MultiNA system. The RGEN-injected embryos exhibited undigested fragments (a+b). Images from a representative embryo injected with varying amounts of Cas9 RNA and sgRNA no. 3a are shown. (C,D) Mutation rates at each injected Cas9 RNA concentration with 25 ng/µL of sgRNA (C) and at each injected sgRNA concentration with 100 ng/µL of Cas9 RNA (D). The mutation rate was calculated as the molar concentration of the undigested fragment (a+b) with AluI as a percentage of the sum of molar concentrations of the undigested fragment (a+b) and the larger digested fragment (b). The molar concentration of each fragment was quantified using the MultiNA Viewer software. Columns and error bars represent mean ± s.e.m. (n = 12). The different letters at the top of the columns indicate significant differences (P<0.05; one-way ANOVA followed by Tukey's HSD test).

  • Table 1. Survival of embryos injected with varying amounts of Cas9 RNA and/or sgRNA
    Table 1.
  • Fig. 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 4. Analysis of off-target mutagenesis.

    (A,B) Heteroduplex mobility assay (HMA) of the mutagenized off-target loci OT2-I4 (OT2-II1) (A) and OT2-II4 (B). The upper panel shows the alignment of the off-target sites with the targeting sequence no. 2. The targeting sequence of sgRNA is indicated in green box, adjacent to NGG protospacer adjacent motif (PAM) sequence in light blue box. The lower panel shows HMA of the off-target loci using genomic DNA mixtures of the 12 embryos. Multiple heteroduplex bands were shown in PCR amplicons from embryos injected with 100 ng/µL of Cas9 RNA and 25 ng/µL of sgRNA no. 2a, whereas a single band was shown from “Control” embryos without injection of the RGENs. (C,D) Subcloned sequences of off-target alterations at OT2-I4 (OT2-II1) (C) and OT2-II4 (D) were identified in the RGEN-injected embryos. Red dashes and letters indicate the identified mutations. The sgRNA targeting sequence and PAM indicate in green and light blue boxes, respectively. The size of deletions and insertions are shown to the right of each mutated sequence (Δ; deletions, +; insertions). Numbers on the right edge indicate the numbers of mutated clones identified from all analyzed clones from each genomic DNA mixture.

  • Fig. 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 5. Dose-dependency of off-target alterations by the RGEN.

    Both the DJ-1 targeting locus and two disrupted off-target loci were analyzed using genomic DNA mixture of the 12 embryos that were injected with dilution series of sgRNA no. 2a and 100 ng/µL Cas9 RNA. (A) Heteroduplex mobility assay (HMA). Each analyzed locus and concentration of the injected sgRNA was shown in the upper side of the panel. (B,C) Subcloned sequence of the targeting locus observed in the embryos injected with either 10 ng/µL (B) or 5 ng/µL (C) of sgRNA no. 2a. (D–G) Subcloned sequence of the off-target locus OT2-I4 (OT2-II1) (D,E) or OT2-II4 (F,G) observed in the embryos injected with either 10 ng/µL (D,F) or 5 ng/µL (E,G) of sgRNA no. 2a. (B–G) Red dashes and letters indicate the identified mutations. The sgRNA targeting sequence and PAM indicate in green and light blue boxes, respectively. The size of deletions and insertions are shown to the right of each mutated sequence (Δ; deletions, +; insertions). Numbers on the right edge indicate the numbers of mutated clones identified from all analyzed clones from each genomic DNA mixture.

  • Fig. 6.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 6. Germ line transmission of the RGEN-induced mutations.

    Each G0 founder that was injected with 100 ng/µL of Cas9 RNA and 25 ng/µL of sgRNA no. 1 was mated with wild-type fish to screen heritable mutations. Mutation sequences identified in each F1 embryo of them by heteroduplex mobility assay (HMA) and subsequent direct sequencing were shown. Red dashes and letters indicate the identified mutations. The sgRNA targeting sequence and protospacer adjacent motif (PAM) indicate in green and light blue boxes, respectively. The size of deletions and insertions are shown to the right of each mutated sequence (Δ; deletions, +; insertions). Numbers on the right edge indicate the numbers of mutated embryos identified from all analyzed embryos. The frequencies of mutations in each founder are indicated on the top of mutation sequences.

  • Table 2. A proposed guideline for design of efficient sgRNAs transcribed by the T7 promoter
    Table 2.
Previous ArticleNext Article
Back to top
Previous ArticleNext Article

This Issue

RSSRSS

Keywords

  • Medaka
  • CRISPR/Cas
  • Genome editing
  • Mutagenesis
  • Off-target alterations

 Download PDF

Email

Thank you for your interest in spreading the word on Biology Open.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Targeted mutagenesis using CRISPR/Cas system in medaka
(Your Name) has sent you a message from Biology Open
(Your Name) thought you would like to see the Biology Open web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Research Article
Targeted mutagenesis using CRISPR/Cas system in medaka
Satoshi Ansai, Masato Kinoshita
Biology Open 2014 3: 362-371; doi: 10.1242/bio.20148177
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Citation Tools
Research Article
Targeted mutagenesis using CRISPR/Cas system in medaka
Satoshi Ansai, Masato Kinoshita
Biology Open 2014 3: 362-371; doi: 10.1242/bio.20148177

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Alerts

Please log in to add an alert for this article.

Sign in to email alerts with your email address

Article Navigation

  • Top
  • Article
    • ABSTRACT
    • INTRODUCTION
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • Acknowledgements
    • Funding
    • Footnotes
    • References
  • Figures & tables
  • Supp info
  • Info & metrics
  • eLetters
  • PDF + SI
  • PDF

Related articles

Cited by...

More in this TOC section

  • Biophysical and biochemical properties of Deup1 self-assemblies: a potential driver for deuterosome formation during multiciliogenesis
  • Conditional targeting of phosphatidylserine decarboxylase to lipid droplets
  • Stability of amino acids and related amines in human serum under different preprocessing and pre-storage conditions based on iTRAQ®-LC-MS/MS
Show more RESEARCH ARTICLE

Similar articles

Other journals from The Company of Biologists

Development

Journal of Cell Science

Journal of Experimental Biology

Disease Models & Mechanisms

Advertisement

Biology Open and COVID-19

We are aware that the COVID-19 pandemic is having an unprecedented impact on researchers worldwide. The Editors of all The Company of Biologists’ journals have been considering ways in which we can alleviate concerns that members of our community may have around publishing activities during this time. Read about the actions we are taking at this time.

Please don’t hesitate to contact the Editorial Office if you have any questions or concerns.


Future Leader Review - Cardiac myosin super relaxation

A new Future Leader Review by Manuel Schmid and Christopher Toepfer discusses the rapidly-expanding field of myosin super relaxation in the context of cardiovascular disease. Read the full Review and their accompanying interview.

Find out more about our Future Leader Reviews – they are an exclusive opportunity for early-career researchers who want to establish themselves in their field.


An interview with Roberta Azzarelli

In an interview, first author Roberta Azzarelli discusses her 3D model of glioblastoma and shares her thoughts on how to improve the professional lives of early-career researchers: formal mentorship programmes, a clearly structured career path and taking part in initiatives such as the Node Network.


News from our sister journals

Development continues to run a successful new webinar series, Development presents…, while Journal of Cell Science has recently welcomed Esperanza Agullo-Pascual as FocalPlane’s new Community Manager. Journal of Experimental Biology’s new special issue highlights the role of comparative biology in tackling climate change and Liz Patton, the new Editor-in-Chief of Disease Models & Mechanisms, sets out her visions and priorities.

Articles

  • Accepted manuscripts
  • Issue in progress
  • Latest complete issue
  • Issue archive
  • Archive by article type
  • Interviews
  • Sign up for alerts

About us

  • About BiO
  • Editors and Board
  • Editor biographies
  • Grants and funding
  • Journal Meetings
  • Workshops
  • The Company of Biologists

For Authors

  • Submit a manuscript
  • Aims and scope
  • Presubmission enquiries
  • Article types
  • Manuscript preparation
  • Cover suggestions
  • Editorial process
  • Promoting your paper
  • Open Access

Journal Info

  • Journal policies
  • Rights and permissions
  • Media policies
  • Reviewer guide
  • Sign up for alerts

Contact

  • Contact BiO
  • Advertising
  • Feedback

Twitter   YouTube   LinkedIn

© 2021   The Company of Biologists Ltd   Registered Charity 277992